arrow
H

Hidekatsu Kuroda

iwate medical university
H指数:23
被引数:2,140

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

WFUMB-Recommended Versus Manufacturer-Optimized Protocols for Ultrasound-Guided Attenuation Parameter in Hepatic Steatosis Assessment: A Retrospective Single-Vendor Multicenter Study

WFUMB推荐与制造商优化协议在超声引导衰减参数评估肝脂肪变中的比较:一项回顾性单一供应商多中心研究

2026-10-280
OA
Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage

阿特珠单抗联合贝伐珠单抗治疗巴塞罗那临床肝细胞癌B2期患者的疗效

2026-09-290
OAAI
Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026

代谢功能障碍相关脂肪性肝病(MASLD)2026年循证临床实践指南

2026-05-120
OAAI
Diagnostic Impact of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Retrospective Study

二维剪切波弹性成像对肝纤维化的诊断影响:一项多中心回顾性研究

2026-05-010
OAAI
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

不可切除性肝细胞癌接受阿替利珠单抗联合贝伐珠单抗治疗后出血事件的临床特征、预测因素及抗血栓治疗的影响

2026-04-210
PRE
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

肝内肿瘤负荷对接受阿替利珠单抗联合贝伐珠单抗治疗的合并肝外转移的肝细胞癌患者预后的影响

2026-04-100
PRE
Comparative diagnostic performance of ultrasound-guided attenuation parameter versus B-mode scoring for hepatic steatosis assessment: an ordinal-scale statistical approach

超声引导下衰减参数与B模式评分对肝脂肪变评估的对比诊断性能:一种序数尺度统计方法

2026-04-020
PRE
Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

淋巴细胞-单核细胞比值预测接受度鲁单单抗联合曲美单抗治疗的HCC患者的生存情况

2026-02-260
PRE
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT

阿替利珠单抗联合贝伐珠单抗用于不适合TACE治疗的超出Up-To-7标准的中间阶段肝癌:REPLACEMENT研究的最终分析

2025-11-030
OAAI
Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial

直接抗病毒药物治疗后,丙型肝炎病毒相关失代偿性肝硬化患者肝脏储备功能和预后的长期变化:一项日本III期试验的五年随访研究

2025-10-300
PRE
A New Model to Predict Survival Time in Patients With Hepatocellular Carcinoma With BCLC Advanced Stage

一种预测BCLC晚期肝细胞癌患者生存时间的新模型

2025-10-150
OAAI
Liver Volumetry Enhances Prediction of Acute Pancreatitis in Acute Liver Failure: A Nationwide Registry Study

肝体积测量增强对急性肝衰竭患者急性胰腺炎的预测:一项全国登记研究

2025-10-010
PRE
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab

基于LDH和CRP的预后评分系统在应用阿替利珠单抗联合贝伐珠单抗治疗的HCC患者中的临床应用价值

2025-09-190
PRE
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination

血清生长分化因子15可作为预测丙型肝炎病毒肝硬化患者病毒清除后预后的新型生物标志物

2025-09-180
OAAI
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis

度鲁特玛联合特瑞普利单抗在合并门静脉血栓和高肿瘤负荷的肝细胞癌患者中的有效性与安全性:一项多中心回顾性分析

2025-09-060
PRE
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma

格瑞特营养风险指数作为不可切除肝癌患者接受度伐利尤单抗联合特瑞普利单抗治疗期间免疫介导不良反应的风险因素的潜在作用

2025-08-200
PRE
Deep learning radiomics of elastography for diagnosing compensated advanced chronic liver disease: an international multicenter study

基于弹性成像的深度学习放射组学在代偿期晚期慢性肝病诊断中的应用:一项国际多中心研究

2025-08-150
OAAI